Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

EMERGO by UL Releases RAMS 2.5, Expanding Automated Medical Device RA/QA Capabilities


News Image

With RAMS 2.5 we greatly add to the depth and breadth of our EU submission tools, and open up a number of significant emerging healthcare markets.

EMERGO by UL, a global medical device and healthcare technology consultancy, released version 2.5 of Regulatory Affairs Management Suite (RAMS), a digital platform that helps manufacturers of medical devices and IVDs to streamline market access and keep track of registrations and regulatory developments. There are now 10,000 medical device and IVD manufacturers active on RAMS and relying on the platform’s blend of free and premium quality assurance and regulatory affairs management services.

New features in RAMS 2.5 include:


  • Two new Smart Builders to aid with creating, collaborating on, and formatting an EU MDR Clinical Evaluation Report (CER) or Clinical Evaluation Plan (CEP). These expand the existing Smart Builder portfolio, which consists of US FDA 510(k), EU MDD CER, MDD Technical File & Design Dossier, and MDR Technical Documentation File submissions. The MDD and MDR builders are compliant with current and upcoming European regulatory schemes to help ease transition between the two.
  • The Product Classification tool, which empowers users to determine the classification of a new device or verify an existing classification in minutes. This feature, which is free to use for a limited time, launches with EU classifications and will expand to cover classifications in other markets.
  • Resources including regulatory process charts, country reference documents, and FAQs for eight new markets across Europe and Asia. The additions give RAMS subscribers access to resources covering 36 healthcare markets worldwide.

Since the first Smart Builder for US FDA 510(k) submissions was released in January 2020 as part of the RAMS 2.1 release, EMERGO by UL has continued to expand the scope of this service to include additional regulatory documentation. Coming soon is an EU MDR Class I Self-Certified CER Smart Builder, along with offerings later in 2020 covering medical device and IVD markets in Mexico and Brazil.

Medical device and IVD manufacturers may set up free RAMS accounts to explore how the tools available on the platform assist them in bringing devices to market and maintaining compliance with greater speed and less cost and effort. Users may also sign up for the eQMS partner service offered by Greenlight Guru, which applies digital automation tools to implement robust quality management system (QMS) capabilities.

“This is our most significant release since the introduction of the first Smart Builder with RAMS 2.1, and arguably since we launched RAMS 2.0 to revolutionize our RA/QA offerings,” said Michael van der Woude, Director and General Manager, Market Access, at EMERGO by UL. “With RAMS 2.5 we greatly add to the depth and breadth of our EU submission tools, and open up a number of significant emerging healthcare markets.”

About Emergo by UL

EMERGO by UL is a leading regulatory consulting firm specializing in global medical device and IVD compliance. Our comprehensive solution is designed to help you achieve and maintain regulatory and commercial success. With a presence on six continents, we can provide real-time service and on-the-ground expertise. Learn more about how we can help you grow at EMERGObyUL.com.

Share article on social media or email:

Accumen Releases First FDA EUA COVID-19 Saliva Testing Kits


News Image

Accumen Inc. is helping healthcare get better, faster. Today the company announced a new partnership with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 saliva testing kits nationally.

“Accumen has been partnering with its clients to strengthen their laboratory supply chain for more than 10 years. Early in the COVID-19 crisis, we identified supply chain gaps and began coordinating resources to meet those evolving needs. As the crisis continued, we were able to provide critical testing supplies like nasopharyngeal (NP) swabs, media and personal protective equipment (PPE) for our clients, and we later made those resources available to other health systems and laboratories across the country to help increase testing efforts,” said Eric Jurinic, Accumen Vice President of Corporate Supply Chain.

Saliva testing for detecting COVID-19 first received FDA Emergency Use Authorization (EUA) in April. This authorization mandated saliva collection solely using Spectrum’s SDNA-1000 saliva collection device based on a trial with Rutgers University. The Spectrum saliva collection kit has been engineered to produce more accurate and sensitive test results, reduce sample collection errors, including for at-home self-collection, reduce labor required for collection and reduce use of valuable PPE.

Additionally, the SDNA-1000 delivers 100% neutralization of the live virus mitigating risk and the threat of unnecessary exposure. It can also preserve and stabilize viral RNA transcripts for transport in extreme and varying temperatures for more than 14 days and for up to one-year post collection in ambient storage.

Accumen offers full kit or saliva collection device only orders, as well as implementation support services. Full details and order contact information are available here: https://accumen.com/resources/collateral/covid-saliva-collection-overview/ .

Accumen continues to provide access to critical PPE for frontline workers produced by U.S.-based manufacturers. The Company’s COVID-19 Supply Chain Catalog with complete product details can be accessed at https://accumen.com/covid-19-resource-center/#supplychaincovidcatalog. Products include the aforementioned COVID-19 saliva testing kits, 3D-printed COVID-19 testing swabs, face shields and disposable masks, gowns, and gloves.

For healthcare providers and institutions that need immediate access to other COVID-19-related resources, Accumen provides laboratory, imaging, blood management rapid response tools and other strategic pandemic resources through its COVID-19 Resource Center at https://accumen.com/covid-19/#accumenresponsetools.

About Accumen Inc.

At Accumen, our focus is helping healthcare get better, faster. Accumen is a technology enabled organization that partners with hospital, health system, commercial laboratory, and payer clients, to provide strategic solutions and services that deliver sustainable performance improvements. Our offerings include lab and imaging transformation, consulting, supply chain optimization, lab outreach, 3D post-processing, patient blood management, test utilization, anemia management, and clinical data exchange. Accumen’s offerings enable our clients to achieve and exceed their cost, quality, and service targets, as well as deliver excellent patient care through evidence-based data and clinical decision support capabilities. Find out more at Accumen.com.

Disclaimer: Accumen has no authority, responsibility, or liability with respect to any clinical decisions made by – or in connection with – a provider’s laboratory, patient blood management, or other operations. Nothing herein and no aspect of any services provided by Accumen is intended – or shall be deemed – to subordinate, usurp, or otherwise diminish any providers’ sole authority and discretion with respect to all clinical decision-making for its patients.

About Spectrum Solutions and Spectrum DNA

Headquartered in Salt Lake City, Utah, Spectrum Solutions and its medical device and services division, Spectrum DNA, focus concentrated industry expertise on engineering innovative end-to-end solutions for both clinical diagnostic projects and commercial product plans. A single-source provider of on-site medical device manufacturing, custom packaging, kitting, and direct-to-consumer fulfillment. Our biosample collection devices, patented technologies, and dedicated services easily deliver measurable process optimization, unprecedented efficiency, and unmatched global scalability. For more information, please visit spectrumsolution.com/SDNA.

Accumen Contact

Kimberly MacDowell, Chief Marketing Officer

Phone: 858.621.3167 | Email: kmacdowell@accumen.com

2111 E Highland Ave, Ste 145 | Phoenix, AZ 85016

Accumen Media Contact

Lisa Osborne, CEO

Rana Healthcare Solutions

Phone: 206.992.5245 | Email: lisa@ranahealth.com

Spectrum Solutions Media Contact

Tim Rush

Springboard5

Phone: 801-208-1100 | Email: tim.rush@springboard5.com

Share article on social media or email:

Digital Pathology Prospers Amid COVID-19 Challenge: Kalorama Report


Kalorama Information logo

The digital systems are finding more and more customers — the growth we project is that the market doubles in seven years.

A new report from market research firm Kalorama Information finds that digital pathology market is 710 million in 2020 and will grow 11.5% each year in the foreseeable future, driven by increasing acceptance of digital systems. The report says the COVID-19 pandemic, while disrupting healthcare in general, also provides a selling point as many pathologists are now at home and need to work digitally. Kalorama Information’s recent study Digital Pathology Markets, 2020-2025, finds a vibrant market that is pushed by the need for faster cancer detection and the enhancements that IT systems, including artificial intelligence solutions provide.

“Glass slides will never become obsolete,” said Bruce Carlson, Kalorama Information’s Publisher. “Pathology starts with a collected tissue that is treated and then placed on a slide. Therefore, glass slides are necessary, even if they are later transferred to a digital scan. “

But the day-to-day work is changing. Automated sample processing and slide strainers have been available for some 10 to 15 years, however end to end automation, digital optics and the artificial intelligence algorithms and high capacity computer power necessary to really make these systems work efficiently have only recently become available. But this histology slide analysis is highly labor intensive and subjective in nature. For at least the past 100-150 years, technologists and pathologists have used a traditional microscope to study tissue slides to diagnose cancer and other diseases. At least this was the scenario until the commercialization of automated image capture and digital image analysis.

“The digital systems are finding more and more customers — the growth we project is that the market doubles in seven years,” Carlson said.

Leica Biosystems is a leader in this space and its products are used in hospital and reference labs, academic medical centers, and biopharma institutions, worldwide. Roche is a top competitor as well. Ten years ago, Roche reinforced its digital pathology business with the acquisition of a competitor that was integrated into Roche’s Ventana Medical business. Roche recently announced the CE-IVD uPath PD-L1 automatic digital pathology product for non-small cell lung cancer (NSCLC).

Applied Spectral Imaging markets PathFusion, a digital pathology solution that combines whole slide imaging, digital FISH analysis and unique digital tissue matching of FISH with H&E/IHC samples. The company reports it has over 3,000 systems installed worldwide.

Visiopharm (Denmark) has been pioneering AI-driven digital precision pathology software since 2001. It works with a number of companies, but the company has recently forged an alliance with Agilent Technologies whereby the companies will co-market Visiopharm’s portfolio of artificial intelligence-driven pathology solutions.

Other companies include Glencoe Systems, Sectra, Epredia and Sunquest. These companies offer a variety of scanner hardware, storage and workflow software solutions and algorithmic based interpretation tools.

The COVID-19 pandemic has had a surprising impact for histology and digital pathology. The pandemic has curtailed all but the most serious surgeries and cancer treatments. Thus an histology lab is receiving the most difficult of tissue samples to process. There is also a workforce shortage of pathologists, with more pathologists retiring than those entering the field and with physical distancing many pathologists are staying out of the lab. At the same time, new rules allow greater use of digital pathology as well as the reading of the test results from remote locations as long as the test was first performed in an authorized CLIA laboratory.

About Kalorama Information:

Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, healthcare, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Share article on social media or email:

EndPoint Technologies and Techsol Corporation join forces to form SciMax Global, to offer Scientific Communications and Medical Affairs Technology Solutions and Services


SCIMAX Medical Affairs Technology Solutions

Maximizing Value for Scientific and Medical Affairs

Satya Sagi, commented, “We are very thrilled to partner with Joe Pierce and his EndPoint team. By forming SciMax Global, I believe we have established a powerful combination of exceptional people, strategy, and solutions from both sides to address key challenges in Medical Affairs.”

Techsol Corporation and EndPoint Technolgoies announced today that both companies have joined forces to form SciMax Global, a new subsidiary company that focuses on providing next-generation technology platform services and value-driven business consulting services for the digital transformation of Scientific Communications and Medical Affairs in the pharmaceutical industry.

With the formation of SciMax Global, Joe Pierce, Founder and President of EndPoint Technologies and Satya Sagi, Founder and CEO of Techsol Corporation along with key team members from both companies have come together to combine the Medical Affairs technology prowess of Techsol and the consulting expertise of EndPoint.

SciMax Global will focus exclusively on Medical Affairs, a third strategic pillar of the new age Pharmaceutical organization, alongside R&D and Commercial. To address key Medical Affairs business challenges for global pharmaceutical and life sciences companies, the company will offer value-driven solutions through 2 broad service categories:

SciMax Consulting Services

  • Subject Matter Expertise to develop and execute Medical Affairs Digital Transformation Strategy utilizing Artificial Intelligence, Analytics, Validation, Compliance, Data Privacy, Strategy and Project Management


SciMax Medical Affairs Platform Services

  • Unified Cloud Solution for Pharma to support Medical Affairs Programs such as Medical Information, Grants, Publications, Investigator Initiated Studies (IIS/IIT), Expanded Access etc
  • Collaboration and Engagement Portals (Med Info, HCP, Patient etc.), Real World Evidence Data Analytics Outcome Assessments

The core SciMax Medical Affairs Technology Platform shall include Techsol’s MedInquirer (MIQ), a leading cloud-based, Medical Information, and Medical Communication System along with the MIQ Self Service Portal and MIQ Mobile App. For more than 5 years, MedInquirer has been used by Global Biopharma Companies and Contact Centers to efficiently, respond to Medical Information Inquiries and to report and triage Adverse Events and Product Complaints. Techsol Corporation first developed MedInquirer in a strategic partnership with one of the largest, US Contact Centers and a top-ten, international, specialty Pharmaceutical Company. SciMax will continue to develop Artificial Intelligence (AI) based solutions, congress technology and conduct MI-Tech Forum events.

Joe Pierce, says, “I’ve been in the industry for nearly 25 years and Techsol’s MedInquirer is simply the best MI solution available. As EndPoint has continued to expand our professional services, we wanted to be able to bring forward and support the best MI solution to the marketplace. This can be achieved now as SciMax. We are extremely excited to be partnering with Sagi and the Techsol team to continue to develop, implement, and support this comprehensive solution.”

Satya Sagi, commented, “We are very thrilled to partner with Joe Pierce and his EndPoint team. By forming SciMax Global, I believe we have established a powerful combination of exceptional people, strategy, and solutions from both sides to address key challenges in Medical Affairs. We have positioned the SciMax platform to become a market leader through our deep domain expertise, industry relationships, continuous technology innovation, consulting capability and strong commitment to the Pharmaceutical Industry.”

Joe Pierce shall be the Chief Executive Officer (CEO) of SciMax Global. He will lead the strategy formation and execution for the new company. All the team members of EndPoint have joined the SciMax team in various strategic roles. Saad Rahman, previously the Director of Product Management of MedInquirer, shall now assume the role of Chief Product Officer (CPO) to lead the technology platform strategy, development, and delivery. Other team members of Techsol will be involved in administrative, business, development, quality assurance, service and support roles. Sagi will continue as Founder and CEO of Techsol Corporation. As a founding board member of SciMax, he will continue to support the executive team in shaping the overall platform strategy and process execution.

About SciMax Global

SciMax Global is an innovative Scientific Communications and Medical Affairs technology solutions provider in the pharmaceutical industry. With a unified cloud Technology Platform and value-driven Consulting Services, SciMax has proven capabilities to help Pharma and Life Science companies for managing different medical affairs programs that improve patient outcomes and care excellence through automation, evidence and insights generation.    

Contact

Joe Pierce

CEO, SciMax Global

+1 630-204-2652

joe.pierce@scimaxglobal.com

101 College Rd East Princeton 08540 NJ

http://www.scimaxglobal.com

About Techsol Corporation

Techsol Corporation specializes in offering cloud-based, information technology services and innovative software solutions to global pharmaceutical, life sciences and healthcare companies. Founded in 2010, a market leader in providing highly configurable process-oriented technology solutions for digitally transforming pharmaceutical business operations across medical affairs, clinical development and drug safety. With offices in Princeton, NJ/ Hyderabad, India/ Seoul, South Korea, Techsol Corporation delivers domain-specific business solutions focused on establishing cross-platform integrations, business process automation, facilitating stakeholder collaboration, risk-based validation, and providing operational insights with advanced AI and data analytics.

About EndPoint Technologies

EndPoint Technologies is dedicated to providing comprehensive technology and business consulting services to life science organizations. Specializing in Medical Affairs in Pharmaceutical and Biotech Companies, EndPoint provides insight and assistance with the process of selecting and implementing new technology, including strategic planning, requirement definition, project management, solutions evaluation, implementation, validation, and training. EndPoint has extensive experience in providing solutions around data privacy, helping companies become and remain compliant. In addition, EndPoint provides systems management, maintenance, and support for a number of widely used software solutions.

Share article on social media or email:

InfoBionic On the Front Lines of EHR Interoperability with Full Disclosure Cardiac RPM


Cardiac episodes are a potential long-term effect for those who recover from COVID-19.

Seventy-three percent of unstructured patient data is inaccessible for analysis.

The current coronavirus pandemic has shown that complete, near real-time health care data is a clear path to improve health outcomes. Achieving that goal moving forward requires that data to be accessible via accurate device and electronic health record (EHR) interoperability. That’s the mantra of leading ambulatory cardiac monitoring provider InfoBionic and a growing healthcare continuum chorus whose true interoperability successes are the roadmap to broader interoperability. “Secure and complete EHR healthcare data sharing will definitely benefit with cloud-based strategies,” InfoBionic CEO Stuart Long said. “But to evolve that journey will require EHR interoperable solutions like full disclosure remote cardiac monitoring and other remote patient monitoring (RPM) solutions to truly begin changing outcomes.”

The Long Road to EHR Interoperability

The first few miles of that electronic health record interoperability journey have been achieved with 96 percent of US hospitals and 86 percent of physician practices now using EHR software.(1)(2) But true interoperability has a long way to go with individual hospitals and health systems using as many as 18 different EHR systems across their facilities and departments.(3) Making matters worse is the fact that 73 percent of unstructured patient data is inaccessible for analysis, which exacerbates the integration and disparate EHR problem and holds back interoperability.(4)

The lack of near real-time access to all-encompassing health condition data makes it nearly impossible to keep up with an evolving pandemic virus. One important aspect of the evolution of knowledge about the virus is that cardiac episodes are a potential long-term effect for those who recover from COVID-19.

The current pandemic has led to broader use of RPM as a means to monitor all types of conditions. The problem is that many solutions lack proven efficacy, the ability to deliver full disclosure data access, and assured integration of that data with EHRs. Many RPM solutions also make it difficult to easily identify the data that requires immediate attention. This is also true of many EHRs that also lack the ability to differentiate and recognize data from disparate sources.(5)

Gaining EHR Interoperability Ground Through RPM and Standards

There is cause for optimism that health care is getting closer to true interoperability. This can be seen with the recent repositioning of The Office of the National Coordinator for Health Information (ONC), Centers for Medicare and Medicaid Services (CMS), and other healthcare regulatory bodies around EHRs. These organizations are at the forefront of the push towards interoperability by transitioning from the meaningful use standard for EHRs to codifying interoperability standards as the benchmark.

In fact, numerous projects like Advancing Standards for Precision Medicine are bringing together major health care organizations to standardize vital sign data language.(6) This is a vital part of interoperability along with application programming interface (API) standardization, universal adoption of Fast Healthcare Interoperability Resources (FHIR) and HL7, and widening of healthcare data types within EHRs.(7)

Wearable health technology and mHealth (mobile health) devices are beginning to explore the viability of EHR interoperability as part of their functionality.(8) The list of ambulatory RPM devices currently spans a limited list of vitals monitoring for things like blood pressure and glucose monitoring among other. The list of RPM devices that have achieved full disclosure of real-time data access and interoperability is even smaller. Although there are certainly RPM devices that monitor the heart, the data that they transmit is often limited in ways that have yet to show efficacy in helping physicians improve health outcomes.

The growing body of evidence shows that COVID-19’s impact on the body’s organs impacts the heart, which can result in healthy people becoming cardiac patients.(9)(10) This is just the tip of the healthcare iceberg showing why remote cardiac monitoring is vital for a broad number of health conditions. The pandemic’s long shadow reveals how RPM in the form of a remote continuous ambulatory cardiac monitor that can ensure full disclosure data and cloud EHR interoperability is vital.

There are clearly a number of gaps that must be bridged to achieve true cloud EHR interoperability, but more providers like InfoBionic are leading the way. “Solutions like the MoMe® Kardia platform are designed to be EHR interoperable along with being versatile to enable transitioning between Holter, Event, and MCT modes remotely”, Long explained. It takes these types of solutions to realize true EHR interoperability that’s simple for ambulatory patients while providing actionable full disclosure health data to the physician, cardiologist and hospitals to improve patient outcomes.”

About InfoBionic

InfoBionic is a digital health company transforming the efficiency and economics of ambulatory remote patient monitoring processes by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices and mobile technology, and bring specific expertise in remote monitoring and cardiology. They have seen first-hand the complexities of traditional cardiac arrhythmia detection and monitoring processes and designed the transformative MoMe® Kardia platform to remove the roadblocks hindering faster, more effective diagnosis and decision-making. Frost & Sullivan bestowed the 2019 North American Remote Cardiac Monitoring Technology Leadership Award upon InfoBionic. For more information, visit http://www.infobionic.com.

1. Non-federal Acute Care Hospital Electronic Health Record Adoption, Health IT Dashboard, dashboard.healthit.gov/quickstats/pages/FIG-Hospital-EHR-Adoption.php

2. “Office-based Physician Electronic Health Record Adoption, Health IT Dashboard, dashboard.healthit.gov/quickstats/pages/physician-ehr-adoption-trends.php

3. Tom Sullivan. “Why EHR data interoperability is such a mess in 3 charts,” Healthcare IT News, April 16, 2018, healthcareitnews.com/news/why-ehr-data-interoperability-such-mess-3-charts

4. “Hyland Healthcare and HIMSS Media publish 2020 Connected Care and the State of Interoperability in Healthcare study results,” Hyland Healthcare, April 20, 2020, hyland.com/hyland-healthcare-and-himss-media-publish-2020-connected-care-and-the-state-of-interoperability-in-healthcare-study-results/

5. Nathan Eddy. “Remote patient monitoring to gain big momentum in 2020,” Health IT News, January 21, 2020, healthcareitnews.com/news/remote-patient-monitoring-gain-big-momentum-2020

6. Kevin Chaney et al. “Standards for Everyday Life: Integrating Emerging Health Data to Advance Precision Medicine,” health IT Buzz, April 9, 2020, healthit.gov/buzz-blog/precision-medicine/standards-for-everyday-life-integrating-emerging-health-data-to-advance-precision-medicine

7. Ben Moscovitch. “Widespread Support for Adopting Tools Needed to Tap Potential of Electronic Health Records,” Pew Trust, September 18, 2019, pewtrusts.org/en/research-and-analysis/articles/2019/09/18/widespread-support-for-adopting-tools-needed-to-tap-potential-of-electronic-health-records

8. Catherine Dinh-Le1et al. “Wearable Health Technology and Electronic Health Record Integration: Scoping Review and Future Directions,” JMIR Publications, November 19, 2018, mhealth.jmir.org/2019/9/e12861/

9. Maria Cohut, Ph.D. “New study warns of COVID-19 impact on cardiovascular health,” Medical News Today, May 19, 2020, medicalnewstoday.com/articles/new-study-warns-of-covid-19-impact-on-cardiovascular-health

10. Ekaterina Pesheva. “COVID-19 may spark cardiac trouble in multiple ways,” Harvard Gazette, April 14, 2020, news.harvard.edu/gazette/story/2020/04/covid-19s-consequences-for-the-heart/

Share article on social media or email:

NuView Life Sciences Secures $90 Million Capital Commitment from Global Emerging Markets for Development of NV-VPAC1™ Cancer Portfolio


The NV-VPAC1™ test has been successfully utilized for in vitro and in vivo diagnostics detecting multiple types of cancer.

This agreement with GEM helps to secure the funding for continued growth and development of NuView’s NV-VPAC1 portfolio… [as] we focus on moving our in vitro cancer diagnostics into the marketplace.

NuView Life Sciences, Inc. announced that it has signed an agreement with GEM Global Yield LLC SCS, a Luxembourg-based private, alternative investment group. Under the accord, GEM agrees to purchase common shares from NuView on a firm commitment basis with an aggregate value of USD$90 million, upon NuView filing a Registration Statement with the U.S. Securities and Exchange Commission (SEC). The agreement provides NuView a 36-month drawdown period.

NuView will use funds to complete a 600-patient in vitro double-blind clinical trial in accordance with the U.S. Food and Drug Administration (FDA) approval process. NuView will also allocate funds for its in vivo diagnostics and Theranostic programs.

NuView controls the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation.

The NV-VPAC1(TM) test has been successfully utilized for in vitro and in vivo diagnostics detecting multiple types of cancer. In clinical studies, the test showed its ability to accurately detect cancer cells and their location not only inside the body, but outside as well, in voided biofluids, confirming the presence of shed cancer cells. NuView is confident the test has the potential for diagnosing a variety of cancers, transforming patient care. The GEM endorsement greatly expedites the process towards potential commercialization.

“This agreement with GEM helps to secure the funding for continued growth and development of NuView’s NV-VPAC1(TM) portfolio. As we focus on moving our in vitro cancer diagnostics into the marketplace, we can simultaneously restart our in vivo diagnostics and Theranostic programs forward,” stated Paul Crowe, Chairman and CEO of NuView.

About The GEM Group:

Global Emerging Markets is a $3.4 billion, alternative investment group with operations in Paris, New York, and Los Angeles. GEM manages a diverse set of investment vehicles focused on emerging markets that provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information: http://www.gemny.com

About NuView Life Sciences, Inc.:

NuView Life Sciences, located in Park City, UT, is an innovative, clinical stage, precision oncology company. NuView’s mission is to change the way cancer is currently diagnosed and treated. The earlier cancer is identified, the better the treatment options are and the greater the chances for successful outcomes. To learn more about NuView Life Sciences, please visit http://www.nuviewlifesciences.com.

Forward-Looking Statements:

This release may contain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 or by the SEC in its rules, regulations, and releases. These forward-looking statements include, among other things, statements of plans, objectives, expectations, or intentions. Forward-looking statements involve risks, uncertainties and assumptions and actual results may differ materially from those expressed in these forward-looking statements. You should not put undue reliance on any forward-looking statements in this communication. We do not have any intention or obligation to update forward-looking statements after the date of this communication, except as required by law.

Share article on social media or email:

TRX Systems Awarded DHS S&T Research Contract for Public Safety In-Building Coverage Analysis Solution


TRX Systems, developer of NEON® Indoor Location Solutions, announced today that it has been awarded a Department of Homeland Security (DHS) Science and Technology Directorate (S&T) research contract to deliver an In-building Coverage and Analysis System (ICAS) using a first responder’s radio and smartphone. The proposed ICAS solution enables simultaneous LMR and LTE coverage characterization that works with existing end-user LMR and FirstNet LTE devices, enables data gathering by minimally trained personnel and provides an easy-to-use interface with a 3D signal map visualization. The solution will quickly inform public safety users about wireless service availability within a building and in other GPS-denied areas and enable the easy identification of communication coverage gaps within specific buildings and across a total service area.

TRX Systems was selected by the DHS Small Business Innovation Research (SBIR) Program to address specific homeland security technology needs and fill gaps in first responder technology. The SBIR program is focused on near-term commercialization and delivery of operational prototypes to federal, state and local emergency responders as well as to internal DHS entities. TRX will receive funding during Phase 1 of the SBIR program to develop, demonstrate, and report results for a prototype ICAS solution. The potential subsequent phases will add the required functionality, hardening, and scalability to make the ICAS solution operational across the public safety community.

“First responders often work indoors, underground, and in other areas where communications are not reliable, so constant situational awareness is difficult to maintain,” said Jeff Kunst, Vice President of Product at TRX Systems. “This DHS S&T award will advance technology to collect the needed data while also making the coverage information and 3D maps more accessible to first responders during operations.”

About TRX Systems

TRX Systems is the developer of NEON GPS-denied location solutions, delivering location, mapping, and proximity solutions where GPS is not available or is unreliable including indoors, underground, in dense urban areas, and where GPS is jammed or erroneous. NEON delivers ubiquitous, low-cost, GPS-denied location through the use of advanced sensor fusion, ranging, and patented dynamic mapping algorithms. NEON location technology provides the foundation for a number of commercial applications, including NEON Personnel Tracker and NEON Signal Mapper.

TRX’s indoor location software development has been supported by the National Science Foundation (NSF), the Defense Advanced Research Projects Agency (DARPA), the U.S. Army, the National Institute of Standards and Technology (NIST), and the Department of Homeland Security (DHS). For more information, visit http://www.trxsystems.com.

Share article on social media or email:

Amarillo Doctor Assigned To Head Key Post For The Texas Chiropractic Association In Austin, TX


Dr. Williams’s primary initiative as the Department Coordinator of Scientific Affairs is the promotion and advocacy of patient-centered, evidence-based care, standardized throughout the state, consistent with current research literature and widely accepted professional treatment guidelines.

The Scientific Affairs department of the Texas Chiropractic Association is focused on education, expertise, excellence in the profession, and education of chiropractic staff. In addition, Scientific Affairs exists to support the activities of Legislative Affairs, State Affairs, Litigation, Public Relations and Insurance Relations and other committees and the TCA membership as necessary.

Some of the committees and their functions under Dr. Williams’s guidance include:

  • Education & Events Committee: Manage TCA sponsorship of educational seminars. Develop educational seminars and webinars to be presented by TCA. Recruit speakers, develop programs and oversee the educational components of the two annual TCA conferences. Provide input into the planning of special events and activities at TCA conferences.
  • Physical Medicine
  • Acupuncture
  • Sports Practitioners
  • Technique
  • Concussion
  • Diagnostic Procedures
  • Electro-Neuro Diagnostic Testing
  • Diagnostic Imaging and Radiology
  • Neurology
  • Nutrition
  • Orthopedics
  • Workers’ Compensation & Designated Doctors

Dr. Williams’s primary initiative as the Department Coordinator of Scientific Affairs is the promotion and advocacy of patient-centered, evidence-based care, standardized throughout the state, consistent with current research literature and widely accepted professional treatment guidelines.

Dr. Williams has been leading the charge for professional standardization, specialization, and integration & collaboration with medical colleagues for several years. Not only is Dr. Williams leading the charge as the Department Coordinator for Scientific Affairs, but he has also served the TCA previously as Chairman of the Public Relations Committee, Chairman of the Chiropractic Development Initiative, and TCA Board Of Directors for 5 years.

Additionally, Dr. Williams also hosts his own podcast called The Chiropractic Forward Podcast. Dr. Williams’s podcast focuses on research findings, the patient-centered practice model, and evidence-informed practice protocols.

Dr. Jeff Williams is an Amarillo chiropractor and owns Creek Stone Integrated Care in Amarillo, TX. He has been a chiropractor in Amarillo, been voted Best Chiropractor in Amarillo, and has been treating the people of the Texas Panhandle since 1998. His office is located at 45th St and I-27. Dr. Williams offers family chiropractic, care for personal injury and car accidents in Amarillo, and wellness care. In addition,

Dr. Williams can be contacted at creekstonecare@gmail.com or by phone at 806-355-3000. http://www.amarillochiropractor.com, or http://www.chiropracticforward.com

Share article on social media or email:

Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Multiple Myeloma


SITC Cancer Immunotherapy Guidelines

SITC Cancer Immunotherapy Guidelines

“Through our immunotherapy clinical practice guidelines, SITC provides an important resource for clinicians in developing treatment plans aimed at the best possible outcomes for their patients,” said SITC President Mario Sznol, MD.

The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated solely to cancer immunotherapy, has published a clinical practice guideline specific to the use of immunotherapy for multiple myeloma, a type of blood cancer.

“The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma,” was developed by an expert panel of leaders in the fields of hematology, oncology, hematopathology, oncology nursing and cancer patient advocacy from across the United States. This immunotherapy-specific guideline provides oncologists and other advanced practice providers a clinical roadmap to provide optimal care for patients who have multiple myeloma.

Our SITC expert panel developed this manuscript to help provide medical oncologists with expert guidance for incorporating the various approved and emerging immunotherapy agents and regimens into their practice,” said Madhav Dhodapka, MD, co-chair of the SITC Multiple Myeloma Immunotherapy Gudeline Expert Panel.

Published in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal, this guideline is an update to the society’s previous 2016 manuscript on hematologic malignancies, which included lymphoma and acute leukemia in addition to multiple myeloma.

“Combination regimens including immunotherapies such as the antibody therapies daratumumab and elotuzumab have become a mainstay in recent years for multiple myeloma and some patients have benefited tremendously,” said Nina Shah, MD, co-chair of the SITC Multiple Myeloma Immunotherapy Guideline Expert Panel. “What’s more, novel agents such as CAR T cell therapies and bispecific T cell engagers are also showing encouraging results in late-stage trials.”

The SITC Cancer Immunotherapy Guidelines are a collection of clinical practice guidelines (CPGs) developed by leading experts to help hematologists and oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines cover immunotherapy treatment recommendations, toxicity management and considerations for patient quality of life. SITC has published CPGs for bladder carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma, hematologic malignancies, non-small cell lung cancer, prostate cancer and renal cell carcinoma. Additional guidelines are in development covering acute leukemia and lymphoma as well as breast cancer, hepatocellular carcinoma, non-melanoma skin cancer and immune-related adverse events.

“SITC as an organization is dedicated to advancing both the science and application of cancer immunotherapy,” said SITC President Mario Sznol, MD. “Through our immunotherapy clinical practice guidelines, SITC provides an important resource for clinicians in developing treatment plans aimed at the best possible outcomes for their patients.”

In addition to the published manuscript, SITC is also offering a number of different opportunities to help clinicians understand and implement the guidelines into their practice. On such resource are the live webinars and on-demand modules hosted on the SITC website. On Sept. 3, 2020, at 7 p.m. EDT, SITC will host a live, free webinar during which attendees will be able to learn more about the treatment recommendations within the Multiple Myeloma guidelines and ask questions of expert faculty. Click here to view past SITC Cancer Immunotherapy Guidelines webinars on-demand.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

About JITC

Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of the Society for Immunotherapy of Cancer featuring an impact factor of 9.913. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.bmj.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on Twitter @jitcancer.

# # #

Share article on social media or email:



Tamara Sawicz, Director of Lifestyles, Vi at Lakeside Village, Receives 2020 Argentum Hero Award


Tamara Sawicz, Director of Lifestyle at Vi at Lakeside Village in Lantana, Fla., has been honored with a 2020 Hero Award from Argentum, the leading national association exclusively dedicated to supporting companies operating professionally managed, resident-centered senior living communities and the older adults and families they serve.

The Hero Awards, presented by Benchmark, recognize ideal representatives of people serving in the senior living field. Nominated by regional company executives and executive directors, these individuals to show the highest levels of excellence, caring, and dedication.

Sawicz was honored for inspiring others, contributing to the community, and changing the lives of residents. In her nomination, Senior Vice President of Human Resources, Learning and Organizational Development Judy Whitcomb said: “With an enthusiastic and genuinely friendly attitude, Tamara exudes a passion for delivering value and benefits to those she works for and with.”

With a background that ranges from television production to social work, Sawicz continually takes action to help residents realize their dreams — whether it is helping veterans share their stories, enabling a resident to realize her life-long goal of publishing a book, or leading creative writing classes to share her love for writing and inspire others. A video project she created on veterans in her community was selected to be part of the Jacob Rader Marcus Center of the American Jewish Archives in Washington, D.C.

“We are so grateful for Tamara’s dedication and the many everyday heroes who work to serve, protect, and care for residents in the best of times and the most challenging of times,” said James Balda, Argentum president and CEO.

All 2020 honorees are profiled in the July/August issue of Senior Living Executive magazine.

About Vi

Headquartered in Chicago, Illinois, Vi operates 10 continuing care retirement communities (CCRCs) across the United States. With more than 30 years of experience as the owner and operator of residential communities for older adults, Vi continues to work toward providing quality environments, services and programs to enrich the lives of those they serve. In 2019, Vi was recognized by Great Place to Work and Fortune as one of the Best Workplaces for Aging Services and was ranked as one of Glassdoor’s “Top 100 Best Places to Work”.

About Argentum

Argentum is the leading national association exclusively dedicated to supporting companies operating professionally managed, resident-centered senior living communities and the older adults and families they serve. Since 1990, Argentum has advocated for choice, independence, dignity, and quality of life for all older adults.

Argentum member companies operate senior living communities offering assisted living, independent living, continuing care, and memory care services. Along with its state partners, Argentum’s membership represents approximately 75 percent of the senior living industry—an industry with a national economic impact of nearly a quarter of a trillion dollars and responsible for providing over 1.6 million jobs. These numbers will continue to grow as the U.S. population ages.

Argentum’s programs and initiatives are driven by its membership. For more information about joining Argentum, please visit argentum.org/membership. Learn more at argentum.org.

Share article on social media or email: